1.World Health Organization, United Nations Children's Fund. Measles mortality reduction and regional elimination strategic plan 2001–2005. Geneva: WHO, 2001.
2.Centers for Disease Prevention and Control. Progress in global measles control and mortality reduction, 2000–2006. Morbidity and Mortality Weekly Report 2007; 56: 1237–1241.
3.World Health Organization, United Nations Children's Fund. GIVS: Global Immunization Vision and Strategy 2006–2015. Geneva: WHO, 2005.
4.Orenstein, WA, et al. Measles eradication: is it in our future? American Journal of Public Health 2000; 90: 1521–1525.
5.World Health Organization. World Health Organization Regional Office for Africa Measles SIAs Field Guide. Geneva: WHO, 2006.
6.Agur, Z, et al. Pulse mass measles vaccination across age cohorts. Proceedings of the National Academy of Sciences USA 1993; 90: 11698–11702.
7.Shulgin, B, Stone, L, Agur, Z. Pulse vaccination strategy in the SIR epidemic model. Bulletin of Mathematical Biology 1998; 60: 1123–1148.
8.Nokes, DJ, Swinton, J. The control of childhood viral infections by pulse vaccination. IMA Journal of Mathematics Applied in Medicine and Biology 1995; 12: 29–53.
9.WHO. Measles vaccines: WHO position paper. Weekly Epidemiological Record 2009; 84: 349–360.
10.Pan, C et al. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus monkeys from measles. Journal of Virology 2010; 84: 3798–3807.
11.Griffin, D, Pan, C, Moss, WJ. Measles vaccines. Frontiers in Bioscience 2008; 13: 1352–1370.
12.Hethcote, HW. The mathematics of infectious diseases. SIAM Review 2000; 42: 599–653.
13.Anderson, RM, May, RM. Infectious Diseases of Humans: Dynamics and Control. Oxford; New York: Oxford University Press, 1991.
14.Grais, RF, et al. Estimating transmission intensity for a measles epidemic in Niamey, Niger: lessons for intervention. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006; 100: 867–873.
15.Scott, S, et al. Estimating the force of measles virus infection from hospitalised cases in Lusaka, Zambia. Vaccine 2004; 23: 732–738.
16.World Health Organization. Progress in measles control: Zambia, 1999–2004. Weekly Epidemiological Record 2005; 24: 213–220.
17.Lowther, SA, et al. Population immunity to measles virus and the effect of HIV-1 infection after a mass measles vaccination campaign in Lusaka, Zambia: a cross-sectional survey. Lancet 2009; 373: 1025–1032.
18.Venables, WN, Ripley, BD. Modern Applied Statistics with S-PLUS, 3rd edn. New York: Springer, 1999.
19.Caceres, VM, Strebel, PM, Sutter, RW. Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clinical Infectious Diseases 2000; 31: 110–119.
20.Gans, HA, et al. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. Journal of the American Medical Association 1998; 280: 527–532.
21.Government of the Republic of Zambia. Zambia Demographic and Health Survey 2001–2002. Central Statistical Office (Zambia) CBHZORCM, ed. Lusaka and Maryland: Central Board of Health and ORC Macro, 2003.
23.Duda, RO, Hart, PE, Stork, DG. Pattern Classification, 2nd edn. New York: Wiley, 2001.
24.Ohuma, EO, et al. Evaluation of a measles vaccine campaign by oral-fluid surveys in a rural Kenyan district: interpretation of antibody prevalence data using mixture models. Epidemiology and Infection 2009; 137: 227–233.
25.Wood, JG, et al. Potential impacts of schedule changes, waning immunity and vaccine uptake on measles elimination in Australia. Vaccine 2009; 27: 313–318.